Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ULTRAGRIS-165

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

Standard Dose
165MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview ULTRAGRIS-165 is listed in Drugs@FDA under application 062645 (ANDA).

Marketing status: Discontinued Active ingredient GRISEOFULVIN, ULTRAMICROCRYSTALLINE Form and strength TABLET;ORAL - 165MG Sponsor PLIVA Submission history Latest submission status date: 2000-07-07 00:00:00.

Structured Monograph

Clinical summary

Approval overview ULTRAGRIS-165 is listed in Drugs@FDA under application 062645 (ANDA). Marketing status: Discontinued Active ingredient GRISEOFULVIN, ULTRAMICROCRYSTALLINE Form and strength TABLET;ORAL - 165MG Sponsor PLIVA Submission history Latest submission status date: 2000-07-07 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
ULTRAGRIS-165 (GRISEOFULVIN, ULTRAMICROCRYSTALLINE) | Drug Monograph | MedicHelpline